Tag: Diamond Therapeutics - Psychedelic Alpha

Introducing Pα+: learn more and subscribe today.

Read more about the article First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health

Post published:April 4, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

Post published:March 21, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Post published:January 24, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Post published:December 12, 2022
Post category:Press Release

Read more about the article Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin

Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin

Post published:March 29, 2022
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin

Post published:August 17, 2021
Post category:Press Release

Read more about the article Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

Post published:June 17, 2021
Post category:Press Release

Read more about the article Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Post published:February 4, 2021
Post category:Press Release

Read more about the article Ontario Brain Institute Increases Investment in Diamond Therapeutics to Accelerate Innovation in Mental Health

Ontario Brain Institute Increases Investment in Diamond Therapeutics to Accelerate Innovation in Mental Health

Post published:January 7, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.